Prometheus forms drug toxicity test deal:
This article was originally published in Clinica
Prometheus Laboratories has sublicensed from DNA Sciences a patent covering a gene test that identifies people who are at potential risk of drug toxicity. The PROPredictRx TMPT test detects two gene variations that are involved in the production of thiopurine S-methyltransferase (TPMT), an enzyme that is important in metabolising thiopurine drugs used to treat automimmune and inflammatory diseases. Patients with an unrecognised TMPT deficiency and who are treated with thiopurines may suffer potentially fatal drug toxicity, says Prometheus, of San Diego, California.